The Galveston National Laboratory (GNL) will be a new, seven-story building containing 83,433 net usable square feet of state-of-the-art BSL2 through BSL4 laboratory space designed and constructed to support the research of the NIAID Biodefense Network. This proposal describes plans for its operation, and how the GNL will meet critical national needs related to the identification and validation of effective countermeasures for both naturally emerging infectious diseases and the threat of bioterrorism. The GNL will be operated as a consolidated functional entity on the UTMB campus, with multiple linkages to established UTMB campus operations allowing the GNL to take maximum advantage of the depth and breadth of technical and professional expertise and resources residing elsewhere in the University. GNL research and facility operations will report to the Director of the GNL, who will report to the Dean of the School of Medicine and President of UTMB. Biosafety and security functions will report directly to UTMB's Vice President for Business Affairs, who is the federally designated Responsible Official at UTMB. Scientific research, building operations, and business activities will be managed by the GNL's central Administrative Core built around an executive leadership team comprised of the Director, Scientific Director, Associate Director for Research, and Associate Director for Facilities. Through a GNL Operations Council and in consultation with the NIAID Program Office, this leadership team will direct a multidisciplinary research effort in support of both the GNL and NIAID Biodefense Network involving the activities of nine Research Support Cores (Emerging and High Risk Pathogens;BSL3 Research;Advanced Veterinary Services;Insectary Services;Collaborative Research Services;Experimental Pathology Services;Advanced Imaging Services;Advanced Technologies;and Regulatory Services) and four Facilities Support Cores (Facilities and Logistics; Biocontainment Engineering;Health, Safety and Training Services;and Security). Research priorities will be established in consultation with the NIAID Program Office and other investigators of the NIAID Biodefense Network and with the advice of a distinguished external Scientific Advisory Board. A field Investigations team managed by the Emerging &High Risk Pathogens Core will work with laboratory support from the Experimental Pathology Core to assist the GNL in responding to any future national emergency due to a newly emergent infectious disease or bioterrorist attack.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
National Biocontainment Laboratory Operation Cooperative Agreement (UC7)
Project #
5UC7AI070083-05
Application #
7903135
Study Section
Special Emphasis Panel (ZAI1-RCG-M (M1))
Program Officer
Boyd, Nancy G
Project Start
2006-05-03
Project End
2012-04-30
Budget Start
2010-05-01
Budget End
2012-04-30
Support Year
5
Fiscal Year
2010
Total Cost
$15,000,000
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Andersson, Jourdan A; Sha, Jian; Kirtley, Michelle L et al. (2018) Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics. Antimicrob Agents Chemother 62:
Beasley, David W C; Brasel, Trevor L; Comer, Jason E (2016) First vaccine approval under the FDA Animal Rule. NPJ Vaccines 1:16013
Sha, Jian; Kirtley, Michelle L; Klages, Curtis et al. (2016) A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates. Clin Vaccine Immunol 23:586-600
Fitts, Eric C; Andersson, Jourdan A; Kirtley, Michelle L et al. (2016) New Insights into Autoinducer-2 Signaling as a Virulence Regulator in a Mouse Model of Pneumonic Plague. mSphere 1:
Tiner, Bethany L; Sha, Jian; Cong, Yingzi et al. (2016) Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague. NPJ Vaccines 1:16020
Andersson, Jourdan A; Fitts, Eric C; Kirtley, Michelle L et al. (2016) New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria. Antimicrob Agents Chemother 60:3717-29
Tiner, Bethany L; Sha, Jian; Kirtley, Michelle L et al. (2015) Combinational deletion of three membrane protein-encoding genes highly attenuates yersinia pestis while retaining immunogenicity in a mouse model of pneumonic plague. Infect Immun 83:1318-38
Rasmussen, Lynn; Tigabu, Bersabeh; White, E Lucile et al. (2015) Adapting high-throughput screening methods and assays for biocontainment laboratories. Assay Drug Dev Technol 13:44-54
Boisen, Matthew L; Schieffelin, John S; Goba, Augustine et al. (2015) Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. Viral Immunol 28:19-31
Falzaran, D; Bente, D A (2015) Animal models for viral haemorrhagic fever. Clin Microbiol Infect :

Showing the most recent 10 out of 43 publications